Evaluation of RNA-Based miR-27a as a Novel Cholesterol-Lowering Agent CSR Proposal

Evaluation of Ribonucleic Acid as a Novel Cholesterol-lowering Agent

Objective

• Investigate the therapeutic potential of microRNA-27a (miR-27a) in regulating cholesterol levels and reducing atherosclerosis in mouse models, aiming to develop a new approach to combat cardiovascular diseases.

Description

• Background: Elevated cholesterol levels contribute to cardiovascular diseases, a leading cause of mortality. Statins, the current standard treatment, have limitations. This study explores the use of miR-27a, a microRNA, as a cholesterol-regulating agent., Methodology: Chemically synthesize miR-27a for stability, optimize liposome-based formulations for effective delivery, and determine safe dosage in mice. Assess safety through liver enzyme levels, monitor blood cholesterol, and evaluate heart function, fat deposits, and arterial plaques in mouse models., Beneficiaries: This research aims to benefit people worldwide, particularly those with high cholesterol and cardiovascular disease risk, offering an alternative to statins with fewer side effects.

Impact

• The main outcome is the development of a miR-27a mimic formulation as a novel therapeutic agent to lower blood cholesterol levels and reduce the risk of heart disease.